Talphera Inc. (TLPH), a specialty pharmaceutical company, on Thursday announced its first quarter financial results, and provided various operational updates.
The company's lead product Niyad is a lyophilized form of nafamostat, a potential anticoagulant, anti-inflammatory and anti-viral agent, and was granted a breakthrough device designation by the FDA.
Q1 2026:
Talphera recorded a net loss of $2.56 million, or $0.04 per share in the first quarter, while in the same period of 2025 it reported a net loss of $2.59 million, or $0.10 per share.
Research and development (R&D) and General and administrative (G&A) expenses combined amounted to $3.95 million, increased from the $2.92 million reported in the previous year. The increase was accounted for by the expenditure for the development of Niyad.Cash and cash equivalents on March 31, 2026, amounted to $21.11 million.
The company received a milestone payment worth $4.1 million in a private placement upon reaching 50% enrolment in an ongoing Phase 3 trial.
Operational Highlights:
In March, the company achieved 50% enrolment in the Phase 3 NEPHRO CRRT study evaluating Niyad as an ICD-10 treatment, or for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment.
TLPH is currently trading at $0.83, up 3.66%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.